Beigene Ltd ADR (ONC)

Jan 6, 2025, 2:00 AM EST - 12 days ago

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Dec 27, 2024, 6:00 AM EST - 22 days ago

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Dec 23, 2024, 6:00 AM EST - 26 days ago

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 7:30 PM EST - 5 weeks ago

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Dec 9, 2024, 8:30 PM EST - 5 weeks ago

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Dec 4, 2024, 6:00 AM EST - 6 weeks ago

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

Dec 2, 2024, 6:01 AM EST - 6 weeks ago

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

Dec 1, 2024, 9:00 AM EST - 6 weeks ago

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

Nov 27, 2024, 6:00 AM EST - 7 weeks ago

European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

Nov 26, 2024, 6:01 AM EST - 7 weeks ago

BeiGene to Present at Upcoming Investor Conferences

Nov 19, 2024, 7:00 AM EST - 2 months ago

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

LH

Nov 19, 2024, 6:00 AM EST - 2 months ago

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Nov 14, 2024, 6:00 AM EST - 2 months ago

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

Nov 12, 2024, 6:00 AM EST - 2 months ago

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

Nov 6, 2024, 1:35 PM EST - 2 months ago

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 6, 2024, 6:01 AM EST - 2 months ago

BeiGene to Present at the Jefferies London Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 2 months ago

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Oct 28, 2024, 6:00 AM EDT - 2 months ago

BeiGene Mourns Death of Beloved Board Member Donald Glazer

Oct 21, 2024, 6:00 AM EDT - 3 months ago

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

Oct 16, 2024, 6:00 AM EDT - 3 months ago

BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024

Oct 4, 2024, 11:50 AM EDT - 3 months ago

Chinese Biopharmaceutical Stocks Surge with Positive Policy Impact

Sep 26, 2024, 6:21 PM EDT - 4 months ago

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

Sep 26, 2024, 6:00 AM EDT - 4 months ago

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

Sep 17, 2024, 7:00 AM EDT - 4 months ago

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

Sep 9, 2024, 7:02 AM EDT - 4 months ago

Phonak + Advanced Bionics sponsor new family film, Rally Caps - Worldwide release on September 10th

Sep 9, 2024, 7:00 AM EDT - 4 months ago

BeiGene Announces Updates to Commercial Leadership Team

Sep 9, 2024, 1:00 AM EDT - 4 months ago

BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024

Aug 28, 2024, 6:01 AM EDT - 5 months ago

BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 7:53 AM EDT - 5 months ago

Top 2 Health Care Stocks That May Plunge In August

HALO

Aug 26, 2024, 6:00 AM EDT - 5 months ago

BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL

Aug 22, 2024, 10:36 AM EDT - 5 months ago

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 7, 2024, 6:00 AM EDT - 5 months ago

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

Jul 23, 2024, 9:00 AM EDT - 6 months ago

MarketVector Indexes Licenses its flagship Ethereum Benchmark Rate to VanEck for ETHV, the pioneering Spot Ethereum ETF

LSCC

Jul 23, 2024, 7:00 AM EDT - 6 months ago

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

Jul 18, 2024, 6:30 AM EDT - 6 months ago

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

Jun 21, 2024, 2:41 PM EDT - 7 months ago

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 14, 2024, 6:00 AM EDT - 7 months ago

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Jun 13, 2024, 7:41 PM EDT - 7 months ago

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region

Jun 4, 2024, 6:01 AM EDT - 8 months ago

BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 24, 2024, 6:00 AM EDT - 8 months ago

BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

May 14, 2024, 4:01 PM EDT - 8 months ago

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

May 8, 2024, 6:00 AM EDT - 9 months ago

BeiGene Reports First Quarter 2024 Financial Results and Business Updates

Apr 26, 2024, 10:34 AM EDT - 9 months ago

BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report

Apr 24, 2024, 4:01 PM EDT - 9 months ago

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

Apr 23, 2024, 6:00 AM EDT - 9 months ago

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Mar 14, 2024, 4:28 PM EDT - 11 months ago

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Mar 14, 2024, 2:17 PM EDT - 11 months ago

US FDA approves BeiGene's esophageal cancer therapy

Mar 13, 2024, 8:00 AM EDT - 11 months ago

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Mar 7, 2024, 5:19 PM EST - 11 months ago

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

Mar 7, 2024, 3:50 PM EST - 11 months ago

US FDA approves expanded use of BeiGene's blood cancer drug